1. Introduction {#sec1-molecules-23-01108}
===============

The roots of *Aconitum szechenyianum* Gay. and *A*. *flavum* Hand.-Mazz., which belong to the *Aconitum* genus of Ranunculaceae, are widely used in folk medicine in Shaanxi province in China \[[@B1-molecules-23-01108]\]. C~19~- and C~20~-diterpenoid alkaloids possessing aconitine-type, 7,17-secoaconitine-type, and napeline-type skeletons, which are the main components of *A*. *szechenyianum* \[[@B2-molecules-23-01108],[@B3-molecules-23-01108],[@B4-molecules-23-01108],[@B5-molecules-23-01108]\], possess anti-inflammatory, analgesic, anticancer, anti-epileptiform, and antiparasitic activities \[[@B6-molecules-23-01108],[@B7-molecules-23-01108],[@B8-molecules-23-01108]\]. *A. szechenyianum* has been preliminarily studied; in that study, several norditerpenoid alkaloids were obtained with an aconitine or 7,17-secoaconitine skeleton, and these skeleton were demonstrated to have anti-inflammatory activities in a dose-dependent manner \[[@B9-molecules-23-01108]\]. This paper reports a new investigation on *A. szechenyianum*, conducted to explore more bioactive lead compounds, and three new, along with two known, C~19~-norditerpenoid alkaloids---szechenyianine D (**1**)*,* E (**2**), F (**3**), 8-*O*-methyl-14-benzoylaconine \[[@B10-molecules-23-01108]\] (**4**), and spicatine A \[[@B11-molecules-23-01108]\] (**5**)---were isolated in different fractions from the previous study ([Figure 1](#molecules-23-01108-f001){ref-type="fig"}). The previous study shows that the active ingredients of *A. flavum* exhibit immunosuppressive effects \[[@B12-molecules-23-01108],[@B13-molecules-23-01108]\], which had not been previously reported from *A. szechenyianum.* Therefore, the immunosuppressive effects of Compounds **1--5** were evaluated in vitro through ConA- or LPS-induced splenocyte proliferation models. Three compounds inhibited ConA- or LPS-induced splenocyte proliferation, revealing for the first time that the roots of *A. szechenyianum* possess immunosuppressive activities.

2. Results {#sec2-molecules-23-01108}
==========

Szechenyianine D (**1**) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C~31~H~43~NO~10~ was derived from the protonated molecular ion peak at *m/z* 590.2979 \[M + H\]^+^ (calcd. 590.2965) in the HR-ESI-MS spectrum. The ^1^H-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) of **1** showed the presence of five aromatic proton signals due to a monosubstituted benzene at δ~H~ 8.00 (2H, d, *J* = 7.4 Hz), 7.54 (1H, t, *J* = 7.4 Hz), and 7.44 (2H, t, *J* = 7.4 Hz), five OMe protons at δ~H~ 3.80(3H, s), 3.37 (3H, s), 3.29 (over-lapped), 3.29 (over-lapped), and 3.21 (3H, s), and two strongly shielded protons at δ~H~ 3.32 (1H, s) and δ~H~ 4.29 (1H, s). The ^13^C-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) displayed 31 carbon resonances. Among them, resonances at δ~C~ 166.4, 133.4, 130.0, 130.0 (C × 2), and 128.7 (C × 2) were attributed to a benzoyloxy group; δ~C~ 62.2, 59.3, 59.0, 55.4, and 50.7 were attributed to five OMe groups; δ~C~ 74.7 and 76.4 were attributed to two oxygenated carbons associated with hydroxyl groups. Out of the 10 oxygen atoms in **1**, **9** are associated with five methoxy groups, two hydroxyl groups, and one benzoyl group, and the remaining one may be a hydroxyl group or an internal ether. The NMR features of the remaining 19 resonances were characteristic of an aconitine-type alkaloid, where the δ~C~ 64.4 and 70.0 resonances were attributed to the two carbons associated with an internal ether. The deduction was confirmed by the chemical shift of C-7 (δ~C~ 64.4) and C-17 (δ~C~ 70.0) to downfield in ^13^C-NMR spectra of **1** compared with C-7 (δ~C~ 49.6) and C-17 (δ~C~ 60.6) of szechenyianine A \[[@B9-molecules-23-01108]\], the signals of which are shielded by oxygen atom. In the HMBC spectrum ([Figure 2](#molecules-23-01108-f002){ref-type="fig"}), correlations of H-5 (δ~H~ 2.41) and H-6 (δ~H~ 4.12) to C-7 (δ~C~ 64.4), and H-1 (δ~H~ 3.45) to C-17 (δ~C~ 70.0), suggested the involvement of an internal ether bond. The correlation of H-14 (δ~H~ 4.84) to the carbonyl carbon signal of the benzoyl group (δ~C~ 166.4) suggested that the benzoyl group was located at C-14. The correlations of OCH~3~ (δ~H~ 3.37) to C-1 (δ~C~ 80.3), OCH~3~ (δ~H~ 3.29) to C-6 (δ~C~ 82.2), OCH~3~ (δ~H~ 3.21) to C-8 (δ~C~ 83.3), OCH~3~ (δ~H~ 3.80) to C-16 (δ~C~ 93.2), and OCH~3~ (δ~H~ 3.29) to C-18 (δ~C~ 76.6) suggested that five methoxyl groups were linked at C-1, C-6, C-8, C-16, and C-18. The correlations of H-12 (δ~H~ 1.84, 2.24) and H-14 (δ~H~ 4.84) to C-13 (δ~C~ 74.7), and H-16 (δ~H~ 3.22) to C-15 (δ~C~ 76.4), suggested that two hydroxyl groups were linked at C-13 and C-15. Thus, the planar structure of **1** was deduced as 14-benzoyloxy-13, 15-dihydroxy-1, 6,8,16,18-pentamethoxyl-7(17)-oxide-aconitane. In the ROESY spectrum ([Figure 2](#molecules-23-01108-f002){ref-type="fig"}) of **1**, the NOE correlations of H-1/H-3, H-3/H-5, H-5/H-10, H-10/H-9, H-10/H-14, H-14/H-9, and H-9/H-6 indicated *β*-orientation of H-1, H-5, H-6, H-9, H-10, and H-14, and *α*-axial configurations of 1-OCH~3~, 6-OCH~3~, and 14-benzoyloxy. NOE correlations of H-6/H-5 and H-5/H-18 revealed *β*-orientation of H-18 and 18-OCH~3~; NOE correlations of H-17/H-7, H-15/16-OCH~3~ revealed *α*-axial orientation of H-16, H-17, and 15-OH and *β*-orientation of 16-OCH~3~, 13-OH, and 8-OCH~3~. Moreover, the NOE correlations of H-1/H-3 and H-5 and the lack of correlation between H-2 and H-5 indicated that ring A (C-1, C-2, C-3, C-4, C-5, and C-11) in **1** was in the chair conformation. Thus, Compound **1** was assigned the name (A-*c*)-14*α*-benzoyloxy-13*β*,15*α*-dihydroxy-1*α*,6*α*,8*β*,16*β*,18*β*-pentamethoxy-7(17)-oxide-aconitane.

Szechenyianine E (**2**) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C~39~H~55~NO~11~ was derived from the protonated molecular ion peak at *m*/*z* 714.3840 \[M + H\]^+^ (calcd.714.3853) in the HR-ESI-MS spectrum. The ^1^H-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) of **2** showed the presence of five aromatic proton signals due to a monosubstituted benzene at δ~H~ 8.01 (2H, d, *J* = 7.5 Hz), 7.56 (1H, t, *J* = 7.5 Hz), 7.45 (2H, t, *J* = 7.5 Hz), four OMe protons at δ~H~ 3.75 (3H, s), 3.30 (3H, s), 3.19 (3H s), and 3.12 (3H, s); one acetoxyl proton at δ~H~ 1.35 (3H, s), and one methylic proton of the hydrocarbon chain at δ~H~ 0.86 (3H, t, *J* = 6.2 Hz). The ^13^C-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) displayed 39 carbon resonances. Among them, the resonances at δ~C~ 166.2, 133.6, 129.9, 129.8 (C × 2), and 128.9 (C × 2) were attributed to a benzoyloxy group; δ~C~ 61.5, 59.4, 58.0, and 55.5 were attributed to four OMe groups, δ~C~ 172.5 and 21.6 were attributed to one acetoxyl group; δ~C~ 173.3 was attributed to C=O, δ~C~ 74.3 and 79.0 were attributed to two carbons associated with the hydrocarbon chain, and δ~C~ 14.3 was attributed to one CH~3~ group. The assignments of the NMR signals associated with **2** were derived from HSQC, HMBC, and ROESY experiments. In the HMBC spectrum ([Figure 3](#molecules-23-01108-f003){ref-type="fig"}), correlations of H-14 (δ~H~ 4.89) to the carbonyl carbon signal of the benzoyl group (δ~C~ 166.4) suggested that the benzoyl group was located at C-14. Correlations of OCH~3~ (δ~H~ 3.19) to C-1 (δ~C~ 82.4), OCH~3~ (δ~H~ 3.12) to C-6 (δ~C~ 83.3), OCH~3~ (δ~H~ 3.75) to C-16 (δ~C~ 90.4), and OCH~3~ (δ~H~ 3.30) to C-18 (δ~C~ 80.0) suggested that four methoxyl groups were linked at C-1, C-6, C-16, and C-18, respectively. Correlations of CH~3~ (δ~H~ 1.32) to 8-OAc (δ~C~ 172.5) suggested that one acetoxyl was linked at C-8, and correlations of H-3 (δ~H~ 2.61, 2.71), H-17 (δ~H~ 4.11), and H-20 (δ~H~ 3.04, 3.92) to C-19 (δ~C~ 173.3) suggested that C=O was linked at C-19. Correlations of H-20 (δ~H~ 3.04, 3.92) to C-17 (δ~C~ 56.7) and C-21 (δ~C~ 33.7), H-21 (δ~H~ 1.51, 1.62) to C-22 (δ~C~ 25), and H-22 (δ~H~ 1.59, 1.68), H-25 (δ~H~ 1.30, 2H, m), and H-26 (δ~H~ 0.86, 3H, t) to C-24 (δ~C~ 31.9) suggested the presence of an *N*-heptyl group. Correlations of H-12 (δ~H~ 2.19, 2.80), H-14 (δ~H~ 4.89), and H-16 (δ~H~ 3.30) to C-13 (δ~C~ 74.3), and H-16 (δ~H~ 3.30) to C-15 (δC 79.0) suggested that two hydroxyl groups were linked at C-13 and C-15, respectively. This compound differed from the known compound (A-*c*)-8*β*-acetoxy-14*α*-benzoyloxy-*N*-ethyl-13*β*,15*α*-dihydroxy-1*α*,6*α*,16*β*,18*β*-tetramethoxy-19-oxo-aconitane \[[@B14-molecules-23-01108]\] only in terms of the substituents on the N atom. According to the ROESY ([Figure 3](#molecules-23-01108-f003){ref-type="fig"}) spectrum, NOE correlations of H-6/H-5 and H-5/H-18 revealed *β*-orientation of H-18 and 18-OCH~3~, *α*-axial orientation of 6-OCH~3~; NOE correlations of H-7/H-15, H-17/H-16 revealed *α*-axial orientation of H-16, H-17, and 15-OH and *β*-orientation of 16-OCH~3~, 13-OH, and 8-OAc. Moreover, the NOE correlations of H-3/H-1/H-10/H-9/H-6/H-5 and the lack of correlation between H-2 and H-5 indicated that Ring A (C-1, C-2, C-3, C-4, C-5, and C-11) in **2** was in the chair conformation, the relative configuration of this compound was confirmed. Thus, the planar structure of **2** was assigned the name (A-*c*)-14*α*-benzoyloxy-8*β*-acetoxyl-*N*-heptyl-13*β*,15*α*-dihydroxy-1*α*,6*α*,16*β*,18*β*-tetramethoxy-19-oxo-aconitane.

Szechenyianine F (**3**) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C~24~H~38~NO~5~^+^ was derived from the ion peak at *m/z* 421.2782\[M\]^+^ (calcd.421.2823) in the HR-ESI-MS spectrum. The ^1^H-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) of **3** showed the presence of a methine proton due to one N=CH group at δ~H~ 9.19 (1H, s), one *N*--CH~2~CH~3~ group at δ~H~ 1.51 (t, *J* =7.2 Hz), 4.01 (dq, *J* =7.2, 13.9 Hz ), and 4.42 (dq, *J* =7.2, 13.8 Hz), and three OMe resonances at δ~H~ 3.38 (3H, s), 3.36 (3H, s), and 3.16 (3H, s). The ^13^C-NMR spectrum ([Table 1](#molecules-23-01108-t001){ref-type="table"}) displayed 24 carbon resonances. Among them, the resonances at δ~C~ 59.8, 56.9, and 56.7 were attributed to three OMe groups, δ~C~ 179.2 was attributed to one N=CH group, and δ~C~ 14.0 and 56.3 were attributed to one N--CH~2~CH~3~ group. Comparison of the NMR data of N--CH~2~CH~3~ and C-19 with those of the known compound **11** in \[[@B15-molecules-23-01108]\] indicated the existence of the ^＋^N=CH group. The assignments of the NMR signals associated with **3** were based on HSQC, HMBC, and ROESY experiments. In the HMBC spectrum ([Figure 4](#molecules-23-01108-f004){ref-type="fig"}), correlations of H-5 (δ~H~ 2.46) and H-17 (δ~H~ 3.79) to C-19 (δ~C~ 179.2) suggested that C-19 was involved in the N=CH group. Correlations of OCH~3~ (δ~H~ 3.18) to C-1 (δ~C~ 80.6), OCH~3~ (δ~H~ 3.36) to C-16 (δ~C~ 81.5) and of OCH~3~ (δ~H~ 3.38) to C-18 (δ~C~ 73.4) suggested that three methoxyl groups were linked at C-1, C-16, and C-18, respectively. Correlations of H-6 (δ~H~ 1.82, 2.20), H-7 (δ~H~2.22), H-9 (δ~H~ 2.47), and H-10 (δ~H~ 2.01) to C-8 (δ~C~ 72.3) and of H-16 (δ~H~ 3.45) to C-14 (δ~C~ 75.0) suggested that two hydroxyl groups were linked at C-8 and C-14, respectively. Thus, the planar structure of **3** was deduced as 8,14-dihydroxy-1,16,18-trimethoxy-19-en-aconitane. In the ROESY spectrum ([Figure 4](#molecules-23-01108-f004){ref-type="fig"}) of **3**, the NOE correlations of H-1/H-5, H-1/H-10, and H-10/H-14 indicated β-orientation of H-1, H-9, H-10, and H-14, and α-axial configurations of 1-OCH~3~, 14-OH. NOE correlations of H-5/H-18 indicated *β*-orientation of H-18 and 18-OCH~3~. NOE correlations of H-17/H-12, H-12/H-16, and H-15/H-16 indicated α-axial configurations of H-16, H-17, and 16-OCH~3~ and *β*-orientation of 8-OH. Thus, Compound **3** was assigned the name 8*β*,14*α*-dihydroxy-1*α*,16*β*,18*β*-trimethoxy-19-en-aconitane.

The roots of *A. szechenyianum* have long been used to treat rheumatic diseases, in which inflammation and suppressive immunoreaction are involved in the pathophysiological process. The immunosuppressive effects of Compounds **1**--**5** were evaluated in vitro by ConA-induced or LPS-induced splenocyte proliferation, which was suppressed in a concentration-dependent manner by **2, 4,** and **5** ([Figure 5](#molecules-23-01108-f005){ref-type="fig"}b,c), with IC~50~ values of 5.780 ± 1.12 μm, 3.151 ± 0.52 μm, and 2.644 ± 0.77 μm (ConA-induced), or 4.293 ± 3.20 μm, 3.852 ± 1.57 μm, and 2.283 ± 1.28 μm (LPS-induced), respectively. These three compounds showed low cytotoxic effect ([Figure 5](#molecules-23-01108-f005){ref-type="fig"}a), with CC~50~ values of 422.85 ± 66.4 μm, 176.35 ± 69.65 μm, and 188 ± 84.15 μm, respectively. The CC~50~/IC~50~ values of **2, 4,** and **5** suggested that these compounds are potential immunosuppressive agents.

These three compounds had a certain immunosuppressive effects, but low cytotoxic effects compared with cyclosporin A. We will conduct further experiments in vivo using the arthritis model in rat induced by adjuvant and arthritis model in mice induced by collagen, to obtain more lead compounds to treat rheumatoid arthritis.

3. Materials and Methods {#sec3-molecules-23-01108}
========================

3.1. General Information {#sec3dot1-molecules-23-01108}
------------------------

Optical rotation indices were determined in methanol on a Rudolph Autopol II digital polarimeter (Rudolph, Hackettstown, NJ, USA). ESI-MS analysis was performed on a Quatro Premier instrument (Waters, Milford, MA, USA). HR-ESI-MS spectra were recorded on an Agilent Technologies 6550 Q-TOF (Santa Clara, CA, USA). 1D- and 2D-NMR spectra were recorded on Bruker-AVANCE 400 (Bruker, Rheinstetten, Germany) and Bruker-AVANCE 600 instrument (Bruker, Rheinstetten, Germany) using TMS as an internal standard. Analytical HPLC was performed on a Waters e2695 Separations Module system coupled with a 2998 Photodiode Array Detector and an Accurasil C-18 column (4.6 mm × 250 mm, 5 μm particles, Ameritech, Chicago, IL, USA). Semipreparative HPLC was performed on a system comprising an LC-6AD pump equipped with an SPD-20A UV detector (Shimadzu, Kyoto, Japan) and an Ultimate XB-C18 (10 mm × 250 mm, 5 μm particles) or YMS-Pack-ODS-A (10mm × 250 mm, 5 μm particles) column. Silica gel was purchased from Qingdao Haiyang Chemical Group Corporation (Qingdao, China).

3.2. Plant Material {#sec3dot2-molecules-23-01108}
-------------------

The roots of *A. szechenyianum* Gay. were collected from the Xi Mountains in Gansu Province of China in July 2014 and identified by senior experimentalist Jitao Wang. A voucher specimen (herbarium No. 20140728) has been deposited in the Medicinal Plants Herbarium (MPH), Shaanxi University of Chinese Medicine, Xianyang, China.

3.3. Extraction and Isolation {#sec3dot3-molecules-23-01108}
-----------------------------

The air-dried and powdered underground parts of *A. szechenyianum* (5.0 kg) were extracted with 80% EtOH at 80 °C (3 × 40 L; 1.5 h). After the removal of EtOH under reduced pressure, the extract (2 L) was dispersed in water (1.5 L), adjusted to pH 0.8 with 9% HCl solution, and extracted with petroleum ether (PE). The acidic water solution was alkalized to pH 10.26 with 25% ammonia solution, extracted with CHCl~3~ three times, and evaporated under pressure to give crude alkaloids (50 g). The crude alkaloids (47 g) were loaded on a silica gel column and eluted with a gradient solvent system (PE/acetone/diethylamine, 50:1:0.1--1:1:0.1) to yield 12 fractions (Fr.1--Fr.12). Fr.3 (2.5 g) was purified by HPLC (YMC-Pack-ODS-A, 10 × 250 mm, 5 μm particles, flow rate of 1.0 mL·min^−1^) with CH~3~OH/H~2~O (83:17) as the mobile phase to obtain **1** (6 mg, t~R~ = 45 min). Fr.4 was purified by HPLC with CH~3~OH/H~2~O (75:25) as the mobile phase to obtain **4** (60 mg, t~R~ = 46 min) and **5** (40 mg, t~R~ = 58 min). Fr.7 was purified by HPLC with CH~3~OH/H~2~O (65:35) as the mobile phase to obtain **2** (7 mg, t~R~ = 50 min) and **3** (7 mg, t~R~ = 56 min). More details of the spectra are provided in the [Supplementary Material](#app1-molecules-23-01108){ref-type="app"}.

*(A-c)-14α-benzoyloxy-8β-acetoxyl-13β,15α-dihydroxy-1α,6α,8β,16β,18β-pentamethoxyl-7(17)--oxide*-*aconitane* (szechenyianine D): A white amorphous powder, \[α$\rbrack_{D}^{23.1}$-9.3 (c 0.043, MeOH), IR (KBr) ν~max~: 3495, 2914, 1719, 1277, 1099, 1031 and 712 cm^−1^; ^1^H-NMR (400 MHz, CDCl~3~) and ^13^C-NMR (100 MHz, CDCl~3~) spectral data, see [Table 1](#molecules-23-01108-t001){ref-type="table"}; *m*/*z* 590.2979 \[M + H\]^+^ (calcd. 590.2965) for C~31~H~43~NO~10~.

*(A-c)-14α-benzoyloxy-8β-acetoxy-N-nonyl-13β,15α-dihydroxy-1α,6α,16β,18β-tetramethoxy-19-oxo-aconitane* (szechenyianine E): A white amorphous powder, \[α$\rbrack_{D}^{23.0}$ + 12.1 (c 0.033, MeOH), IR (KBr) ν~max~: 3471, 2933, 2822, 1717, 1453, 1278, 1098, and 712 cm^−1^; ^1^H-NMR (600 MHz, CDCl~3~) and ^13^C-NMR (150 MHz, CDCl~3~) spectral data, see [Table 1](#molecules-23-01108-t001){ref-type="table"}; *m*/*z* 714.3840 \[M + H\] ^+^ (calcd.714.3853) for C~39~H~55~NO~11~.

*8β,14α-dihydroxy-1α,16β,18β-trimethoxy-19-en-aconitane* (szechenyianine F): A white amorphous powder, \[α$\rbrack_{D}^{22.9}$-17.4 (c 0.013, MeOH), IR (KBr) ν~max~: 3381, 2933, 1630, 1455, 1376, 1096, and 1030 cm^−1^; ^1^H-NMR (400 MHz, CDCl~3~) and ^13^C-NMR (100 MHz, CDCl~3~) spectral data, see [Table 1](#molecules-23-01108-t001){ref-type="table"}; *m*/*z* 421.2782 \[M\]^+^ (calcd.421. 2823) for C~24~H~38~NO~5~^+^.

3.4. MTT Assay {#sec3dot4-molecules-23-01108}
--------------

Splenocytes (4 × 10^5^ cells/well) were incubated in triplicate at 37 °C in a humidified incubator with 5% CO~2~ and 95% air. The assay was performed in a 96-well format, and different concentration of Compounds **1**--**5** (0.16--100 μm) and CsA（2μm）were added. The cells cultured with media alone were used as controls. Approximately 48 h later, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/mL, Sigma) was added to each well. The plates were then incubated for another 5 h. Approximately 150 μL of DMSO (Sigma) was then added to each well. Optical density was measured at 570 nm (BioTek, PowWave XS2, VT, USA). The IC~50~ and CC~50~ values were calculated according to the dose curves generated by plotting the percentage of viable cells against the test concentration on a logarithmic scale by using SPSS 15.0. CsA (Cyclosporine A, Sigma, Chicago, IL, USA) was used as a positive control.

3.5. ConA- and LPS-Induced Assay {#sec3dot5-molecules-23-01108}
--------------------------------

Splenocytes (4 × 10^5^ cells/well), different concentration of Compounds **1**--**5** (0.16--100 μm), and CsA（2 μm）in 96-well plates at 37 °C in a 5% CO~2~ atmosphere were cultured in triplicate for 48 h using ConA (2 μg/mL, Sigma) or LPS (1 μg/mL, Sigma). The cells cultured with media alone were used as controls. The cells were pulsed at 0.25 μCi/well of \[^3^H\]-thymidine for 8 h before the end of the culture period and then harvested onto glass fiber filters. \[^3^H\]-thymidine incorporation was measured using a beta scintillation counter (MicroBeta Trilux, PerkinElmer Life Sciences, Boston, MA, USA).

**Sample Availability:** Samples of the compounds **4**--**5** are available from the authors.

The spectra of Compounds **1**--**3** are available online at <http://www.mdpi.com/1420-3049/23/5/1108/s1>.

###### 

Click here for additional data file.
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###### 

Cytotoxicity on splenocytes and inhibition on ConA- or LPS-induced splenocyte proliferation of Compounds **1**--**5**. (**a**) Cytotoxicity of Compounds **1**--**5** on BALB/c mice splenocytes. (**b**) Inhibition of Compounds **1**--**5** on ConA-induced splenocyte proliferation. (**c**) Inhibition of Compounds **1**--**5** on LPS-induced splenocyte proliferation. Results are mean ± S.D. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, treatment group versus control.
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###### 

^1^H-NMR and ^13^C-NMR spectral data for Compounds **1**--**5**.

  NO.                    1                   2                     3                 4                     5                                                
  ---------------------- ------------------- --------------------- ----------------- --------------------- ------- -------------------------------- ------- -------
  1                      80.3                3.45 (d, 7.6)         82.4              3.07 (d, 8.3)         80.6    3.40 (m)                         82.8    82.8
  2                      29.6                1.22 (m, H-2a)        25.3              1.43 (m, H-2a)        20.6    1.40 (m, H-2a)                   33.6    33.6
  2.41 (m, H-2b)         1.87 (m, H-2b)      1.72 (m, H-2b)                                                                                                 
  3                      29.9                1.22 (m, H-3a)        33.4              2.61 (m, H-3a)        25.5    1.94 (m)                         72.0    71.9
  1.40 (m, H-3b)         2.71 (m, H-3b)                                                                                                                     
  4                      43.5                                      37.8                                    48.6                                     43.3    43.2
  5                      42.3                2.41 (d, 6.7)         47.6              2.29 (d, 6.7)         38.4    2.46 (m)                         46.2    45.9
  6                      82.2                4.12 (d,6.7)          83.3              4.04 (d, 6.7)         24.6    1.82 (m, H-6a)2.20 (m, H-6b)     83.6    83.7
  7                      64.4                3.32 (s)              50.9              2.63 (s)              45.1    2.22 (m)                         45.4    43.3
  8                      83.3                                      91.3                                    72.3                                     82.6    82.5
  9                      44.5                2.59 (t, 5.8)         43.5              2.84 (t, 5.8)         53.8    2.47 (m)                         42.7    45.4
  10                     40.8                2.26 (m)              41.1              2.19 (m)              38.3    2.01 (m)                         41.7    41.6
  11                     50.9                                      50.0                                    51.2                                     50.8    50.8
  12                     35.5                2.24 (m, H-12a)       35.6              2.80 (m, H-12a)       27.8    2.04 (m, H-12a)1.26 (m, H-12b)   36.5    36.5
  1.84 (m, H-12b)        2.19 (m, H-12b)                                                                                                                    
  13                     74.7                                      74.3                                    43.3    1.96 (m)                         75.0    75.0
  14                     78.8                4.84 (d, 5.8)         78.8              4.89 (d, 5.8)         75.0    4.21 (t, 4.9)                    79.7    79.8
  15                     76.4                4.65 (d, 5.4)         79.0              4.49 (dd, 2.9, 5.4)   39.5    2.27 (m, H-15a)                  78.0    78.7
  2.40 (m, H-15b)                                                                                                                                           
  16                     93.2                3.22 (d, 5.4)         90.4              3.30 (d, 5.4)         81.5    3.45 (m)                         93.6    93.6
  17                     70.0                4.29 (s)              56.7              4.11 (s)              68.1    3.79 (s)                         62.7    61.4
  18                     76.6                3.54(d, 8.2, H-18a)   80.0              3.78(d,8.2,H-18a)     73.4    3.71 (2H, m)                     77.2    77.2
  3.46 (d,8.2, H-18b)    3.06(d,8.2,H-18b)                                                                                                                  
  19                     50.3                3.62(d,11.9,H-19a)    173.3                                   179.2   9.19 (s)                         49.2    49.2
  3.72(d,11.9,H-19b)                                                                                                                                        
  20                                                               45.5              3.04 (m, H-20a)                                                        
                                                                   3.92 (m, H-20b)                                                                          
  21                                                               33.7              1.51 (m, H-21a)                                                        
                                                                   1.62 (m, H-21b)                                                                          
  22                                                               25.0              1.59 (m, H-22a)                                                        
                                                                   1.68 (m, H-22b)                                                                          
  23                                                               29.6              1.30 (m, H-23a)                                                        
                                                                   1.23 (m, H-23b)                                                                          
  24                                                               31.9              1.30 (m, H-24a)                                                        
                                                                   2.26 (m, H-24b)                                                                          
  25                                                               22.9              1.30 (2H, m)                                                           
  26                                                               14.3              0.86 (3H, t,6.2)                                                       
  8-OAc                                                            172.5                                                                                    
                                                                   21.6              1.35 (s)                                                               
  8-OCH~2~CH~3~                                                                                                                                             57.4
  8-OCH~2~CH~3~                                                                                                                                             15.5
  1-OCH~3~               55.4                3.37 (s)              55.5              3.19 (s)              56.7    3.16 (s)                         56.1    56.1
  6-OCH~3~               59.3                3.29 (s)              58.0              3.12 (s)                                                       59.4    58.8
  8-OCH~3~               50.7                3.21 (s)                                                                                               50.1    
  16-OCH~3~              62.2                3.80 (s)              61.5              3.75 (s)              56.9    3.36 (s)                         61.4    62.6
  18-OCH~3~              59.0                3.29 (s)              59.4              3.30 (s)              59.8    3.38 (s)                         59.3    59.3
  N-[CH~2~]{.ul}CH~3~                                                                                      56.3    4.01 (dq, 13.9, 7.2)             47.6    47.6
  4.42 (dq, 13.9, 7.2)                                                                                                                                      
  N-CH~2~[CH]{.ul}~3~                                                                                      14.0    1.51 (t, 7.2)                    13.6    13.5
  ArC=O                  166.4                                     166.2                                                                            166.5   166.4
  ArC-1′                 130.0                                     129.9                                                                            130.4   130.6
  3′, 5′                 128.7               7.44 (t, 7.4)         128.9             7.45 (t, 7.5)                                                  128.6   128.6
  2′, 6′                 130.0               8.00 (d, 7.4)         129.8             8.01 (d, 7.5)                                                  129.9   129.9
  4′                     133.4               7.54 (t, 7.4)         133.6             7.56 (t, 7.5)                                                  133.1   133.1

δ in CDCl~3~, in ppm from TMS; coupling constants (*J*) in Hz; ^1^H-NMR at 400 MHz and ^13^C-NMR at 100 MHz for Compounds **1, 3, 4**, and **5**, and ^1^H-NMR at 600 MHz and ^13^C-NMR at 150 MHz for Compound **2**.

[^1]: These authors contribute equally to this work.
